[Associations of serum neuromarkers with clinical features of Parkinson's disease].

OBJECTIVE: To evaluate the clinical and laboratory correlation of biomarkers with anti- and pro-apoptotic activity with the severity of motor and non-motor symptoms depending on the progression rate of Parkinson's disease (PD).

MATERIAL AND METHODS: A wide range of non-motor symptoms (emotional-affective, cognitive, psychotic and behavioral disorders, fatigue, sleep disorders and autonomic disorders) was evaluated using validated scales and a number of serum neuromarkers responsible for neuroplasticity and neuronal survival processes (BDNF, PDGF, cathepsin D) in 71 patients with PD (mean age 65 (55; 70) years, disease duration 7 (4; 9) years, age of onset 57 (49; 62) years).

RESULTS: The concentration of biomarkers (BDNF, PDGF and cathepsin D) was the lowest in the group of patients with a rapid PD progression rate ( p <0.001, p =0.001 and p =0.031, respectively), the severity of motor and most non-motor symptoms was higher ( p =0.023 and p =0.001, respectively) compared to middle and slow progression rate. There were correlations between BDNF concentration and the severity of depression ( r =-0.63, p <0.001), apathy ( r =-0.48, p <0.001), impulsive behavioral disorders ( r =0.500, p <0.001), level of cognitive functions ( r =0.54, p <0.001), motor symptoms ( r =-0.43, p <0.001); between PDGF level and the severity of motor manifestations of PD ( r =-0.30, p =0.011), depression ( r =-0.70, p <0.001), apathy ( r =-0.460, p <0.001), the degree of severity of behavioral disorders ( r =0.742, p <0.001). No significant correlations were observed between the level of cathepsin D and the severity of clinical manifestations of PD, which indicates the connection of cathepsin D with the general pathogenesis of PD.

CONCLUSION: The possibility of using serum proteins of the neurotrophin subfamily and the protein associated with autophagy, cathepsin D, as biomarkers that determine the prognosis of PD, is considered.